The Trump administration was warned that its policy changes undermining the Affordable Care Act would cause disruption to healthcare coverage and likely increase taxes, according to a leaked internal memo, first reported by Politico. CMS Administrator Seema Verma penned the memo in August 2018 and outlined how several policy changes could negatively impact the ACA market.
As Medicare for all continues to gain traction among American voters and more Democratic presidential nominees take up the platform, the American Medical Association has decided not to support such an initiative.
HHS, with the Departments of Labor and Treasury, has issued a new rule to expand the use of health reimbursement coverage, which provide tax-preferred funds for employees to buy their own insurance on the individual market.
Proposed rules to mitigate one of the biggest obstacles to value-based care––interoperability––and provide patients with access to their own health information for free are being met with privacy and security concerns from industry stakeholders.
Brand-name drugs are likely to keep rising in price, even though the top-selling ones have been available for years and have already seen their costs skyrocket, according to a new study published in JAMA.
CMS published its final rule to update the programs of all-inclusive care for the elderly (PACE), which provides comprehensive medical and social services to help keep elderly individuals who qualify for nursing homes in their homes longer.
The Trump administration is expected to release an executive order this week that mandates the disclosure of healthcare prices across the industry, The Wall Street Journal reported. If enacted, the executive order could turn the traditionally opaque healthcare industry on its head.
CMS finalized a rule that aims to boost transparency of the cost of prescription drugs in Medicare Part D and enable Medicare Advantage plans to negotiate better prices for medicines. Notably, the final version backs off a controversial proposal that would have allowed Medicare Part D plans to exclude certain drugs if prices rise beyond a threshold.